Printed from the IBC Life Sciences Web site on September 15, 2014 8:54 PM ET.
Page location: http://www.ibclifesciences.com/TIDES/overview.xml
May 03-06, 2015
Town and Country Resort Hotel
San Diego, CA
Peptide R&D: Advances and Opportunities
Nader Fotouhi, Ph.D., Chief Scientific Officer, Global Alliance for TB Drug Development (TB Alliance); Former Vice President, Head of Discovery Technologies, Hoffmann-La Roche
Pharmaceutical Protein and Peptide Engineering
Lars F. Iversen, Ph.D., Corporate Vice President, Diabetes Protein Engineering, Novo Nordisk, Denmark
Aptamer Nanotechnology for Therapeutic Nanoparticles
Omid Farokhzad, M.D., Associate Professor; Director, Laboratory of Nanomedicine and Biomaterials, Brigham and Women's Hospital, Harvard Medical School
Peptide-Based Vaccines in the New Era of Cancer Immunotherapy
Eric von Hofe, Ph.D., President, Antigen Express, Inc.
PeptiDream: From Bench to IPO
Patrick C. Reid, Ph.D., Chief Scientific Officer, PeptiDream Inc., Japan and U.S.A.
Join our priority contact list and receive the latest event news.
Special Discounted Hotel Rate Available Until Friday, April 18, 2014. To book your room, call 1-(800)-843-6664 and reference TIDES 2014.
The global market for DNA oligonucleotides tops $700 million annually
Controlled release polymer systems are used by over 100 million people each year, and the annual worldwide market of controlled release polymer systems is now estimated at $100 billion.
More than 160 unique companies from 20 different countries attended TIDES last year
The peptide API business represents about $900 million, with sales of final formulated drugs representing $14-15 billion worldwide.
Antisense Technology: Current Status and Future
Stanley T. Crooke, M.D., Ph.D.
Chief Executive Officer, Isis Pharmaceuticals, Inc.
May 3-6, 2015
Town and Country Hotel
San Diego, CA
Jeffrey Baker, Ph.D.; David C. Blakey, Ph.D.; Jared A. Gollob, M.D.; and Eric von Hofe, Ph.D.
» Watch Full TIDES 2014 Keynote Presentations and Speaker Interviews
Join 750 global oligonucleotide and peptide professionals at TIDES 2014, where you will access the latest science, technologies and regulations needed to advance your product from discovery to clinic to market.
Our 2014 program includes tons of exciting new updates, speakers and topics to keep you on the pulse of this evolving industry. Whether your focus is on oligonucleotides or peptides, discovery or manufacturing, TIDES 2014 is the one-stop conference to advance your research, development and process chemistry efforts forward.
Brochure Now Available
» Download Today!
TIDES Pre-Event Podcasts Now Available!
» Learn More
TIDES 2013 Keynote Presentations Now Available!
» Learn More
Accelerate Your Pipeline and Improve Your Manufacturing Operations
by accessing case studies, regulatory updates and lessons learned from 100 industry and academic presentations
Benchmark Your Current Development Efforts
by hearing preclinical and clinical successes and failures from peptides and oligonucleotides currently in development
Access Novel Technologies and Cutting-Edge Science
in the exhibit and poster hall, featuring over 75 exhibitors and 30 peer-submitted posters
Forge Scientific and Business Partnerships
by meeting 750 global oligonucleotide and peptide professionals during networking luncheons, cocktail receptions and refreshment breaks
"TIDES is the premier venue to network with the experts in peptide and oligonucleotide development and to be on the pulse of current status and future trends in Biotech and Pharma." - Alex Fӓssler, Ph.D., COO Europe, Bachem AG, Switzerland
"TIDES is an excellent opportunity to connect with the Oligo Industry, staying abreast of the latest developments while formulating strategies for the future." - Giuseppe Whelan, Project Leader, GlaxoSmithKline
"One of the great things about TIDES, in addition to the excellent program content, is the large exhibit hall which enables me to meet with many of the most relevant suppliers with just one trip." - Christoph Rosenbohm, Ph.D., Senior Director, Research Operations, Santaris Pharma A/S, Denmark
"Very interesting presentations from industry and academia make TIDES an excellent opportunity to know the hot-topics in peptide therapeutics. The dynamic, friendly atmosphere creates good networking opportunities." - Jose De Chastonay, Ph.D., MBA, Chief Marketing Officer, Bachem Group
"TIDES is THE venue for oligonucleotides and peptides together. The complete package only exists in one setting and that's TIDES. There is no forum that has the same level of expertise in one place at one time other than TIDES." - Scott Petersen, Ph.D., Chief Scientific Officer, Liposciences, Inc.
"The TIDES series of conferences is an indispensable catalyst for the industry to bring people together to share knowledge and address topics of common interest and ensure that we can help our business and the industry to grow and flourish... It's a special, special event. I always enjoy myself and find it incredibly enriching." - Lester Mills, Ph.D., MBA, Head of M&A, BASF